424P - Patient profile and therapeutic management in Glioblastoma (GBM): A subgroup analysis of a large prospective observational study of the Neuro-Oncol...

Date 28 September 2014
Event ESMO 2014
Session Poster Display session
Topics Anticancer Agents
Central Nervous System Malignancies
Biological Therapy
Presenter Juan Sepúlveda
Citation Annals of Oncology (2014) 25 (suppl_4): iv137-iv145. 10.1093/annonc/mdu330
Authors J.M. Sepúlveda1, J. Vieitez2, S. Vazquez3, A. Rodriguez Sanchez4, O. Gallego5, L.M. Rodríguez6, J. Andrade7, F. González8, E. Pujol9, M. Gil Gil10
  • 1Medical Oncology, University Hospital 12 de Octubre, 28041 - Madrid/ES
  • 2Medical Oncology, Hospital Universitario Central de Asturias, Oviedo/ES
  • 3Oncology, Hospital Universitario Lucus Augusti, 27003 - Lugo/ES
  • 4Medical Oncology, Hospital de León, ES-24008 - Leon/ES
  • 5Medical Oncology, Hospital Sant Pau, Barcelona/ES
  • 6Medical Oncology, Hospital Universitario de Canarias, Tenerife/ES
  • 7Medical Oncology, Hospital Virgen de la Salud, Toledo/ES
  • 8Medical Oncology, Quirón Madrid, Madrid/ES
  • 9Medical Oncology, Hospital Lozano Blesa, Zaragoza/ES
  • 10Medical Oncology, Institut Català Oncologia, l´Hospitalet/ES



To date, sociodemographic data and therapeutic management have not been well explored in GBM patients (p) at Spanish level. The GEINO-10 study was designed to evaluate the clinical profile and therapeutic behaviors in p with intra-axial brain tumours (BT). GBM, the most common malignant adult tumour, is the most frequent in our database.


Data on p with intra-axial BT were collected over years (2010-2013). Out of 397 p included, 67% had GBM. We aim to undertake an exploratory subanalysis of this poor prognostic group to describe the clinical and pathological characteristics as well as the therapeutic management of GBM in 28 Spanish institutions.


265 p with GBM were enrolled. Median age: 61 years (19-83); male/female (%): 63/37; ECOG 0/1 (%): 23/48. 55% had comorbidity. 10% had history of previous cancer . Symptoms at diagnosis: 35% focal neurological deficit; 28% cognitive impairment; 19% epileptic seizures and 7% ataxia. Location (lobe): 32.5% frontal, 32% temporal, 15% parietal and 6% occipital. Treatment (Tx) received: 42% complete resection, 42% partial, 10% stereotactic biopsy and 6% open biopsy. 3% of p received neoadjuvant temozolomide (TMZ) ± bevacizumab (BV) into a clinical trial. 94% of p received radiotherapy (RT) (72% focal, 21% whole-brain and 6% hemi-brain) concomitant with TMZ. After the concomitant phase, 82% of p received active chemotherapy (CT) with a median of 5 cycles (1-14) and 97% of them with TMZ. Out of 188 p evaluable, a disease control rate was achieved in 70% and the median Progression Free Survival was 10.4 months (95%CI: 9-11.8). At progression, 41% of total p received Tx: 13% surgery, 8% RT and 95% CT (52% BV ± CPT11, 15.5% TMZ, 12% nitrosoureas, 4.5% dacomitinib and 9% other). Overall Survival achieved was 23.6 months (95%CI: 16-31.2).


At diagnosis, almost all patients received RT + TMZ after surgery or biopsy. 41% were treated at progression, half of them with a BV regimen. The exceptionally good survival could reflect a selection of p with good PS. This information can be useful to homogenize and to optimize Tx and for future clinical trials in GBM.


All authors have declared no conflicts of interest.